News Focus
News Focus
Post# of 257391
Next 10
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

Re: ghmm post# 154669

Saturday, 12/29/2012 7:41:00 PM

Saturday, December 29, 2012 7:41:00 PM

Post# of 257391

I had never heard of them till the Shire deal a little bit ago. Haven't sat down and done any research. Now that they've dropped from the Shire announcement may be a good time. It appears that they have a big library (I thought I saw 40,0000 somewhere) and with multiplatform capabilities I wonder if more collaborations are likely.

Yeah, per a recent CC I listened to, management seemed to guide for future deals and hopefully of greater economic impact to ARWR. Could just be talking the book of course. They do have a near-term binary event in Phase 2 OS data to read out in early 2013 on a partnered NSCLC drug that a partner (Cerulean) is developing. Presumably the odds aren't that great but who knows. They seem to be positioning their Hep B RNAi therapeutic as a key asset and that's due to enter the clinic next year. They also have a boom-or-bust obesity drug called adipotide that's now in Phase 1.

I recently sold out of BIOD as I needed to take the tax-loss but also because I thought their recent CC was rather disappointing on several fronts. I'll be looking to replace that with at least one major boom-or-bust play next year just because it's always fun to have one of these sub-$50M lotto tickets in your biofolio, right? LOL I'm considering ARWR, RTRX, and GNVC for what might just be one highly speculative slot in my biofolio.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today